Mismatch Repair Status Is a Predictive Factor of Tumour Response to 5-Fluorouracil and Irinotecan Chemotherapy in Patients with Advanced Colorectal Cancer
Authors:
- R. BendardafRBR. Bendardaf
- H. LamlumHLH. Lamlum
- R. RistamÄKiRRR. RistamÄKi
- E. KorkeilaEKE. Korkeila
- K. SyrjÄNenKSK. SyrjÄNen
- S. PyrhÖNenSPS. PyrhÖNen
- 1 January 2007
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 28 (4) , 212-220
Abstract
To determine the association between DNA mismatch repair (MMR) protein expression and response to chemotherapy in patients with advanced colorectal cancer (CRC). Using immunohistochemistry, tumour expression of 2 MMR genes, hMLH1 and hMSH2, was assessed in 86 patients with advanced CRC, who were treated with either irinotecan alone or in combination with 5-flurouracil/folinic acid. Weak/negative staining in the tumours was associated with the presence of metastases at diagnosis (p = 0.026) and with the time for metastases to appear (p = 0.0001). An objective response to treatment was observed in 32/56 (57%) patients who had tumours with negative/weak MMR protein expression (p = 0.001), compared to 17% of patients with tumours with moderate/strong expression. Those who had tumours with weak/absent expression of either hMLH1 or hMSH2 who received the combination therapy were more likely to show an objective response (p = 0.0001). Advanced CRC patients whose tumours have deficient MMR demonstrate a shorter time to metastasis than those with normal hMLH1/hMSH2 expression. Patients with MMR-deficient tumours are also more likely to benefit from combination chemotherapy (irinotecan plus 5-flurouracil/folinic acid).Keywords
This publication has 27 references indexed in Scilit:
- Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinomaOncogene, 2004
- Chemotherapy in metastatic colorectal cancerTechniques in Coloproctology, 2004
- Response to Chemotherapy (Irinotecan plus 5-Fluorouracil) in Colorectal Carcinoma Can Be Predicted by Tumour DNA ContentOncology, 2004
- Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon CancerNew England Journal of Medicine, 2003
- High‐frequency microsatellite instability predicts better chemosensitivity to high‐dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resectionInternational Journal of Cancer, 2002
- Microsatellite Instability Is a Predictive Marker for Survival Benefit from Adjuvant Chemotherapy in a Population-Based Series of Stage III Colorectal CarcinomaClinical Colorectal Cancer, 2001
- Mismatch repair in correction of replication errors and processing of DNA damageJournal of Cellular Physiology, 2001
- ABC of colorectal cancer: Treatment of advanced diseaseBMJ, 2000
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Microsatellite instability in sporadic-colon-cancer patients with and without liver metastasesInternational Journal of Cancer, 1997